Specificity: Recognizes the EGFR protein
Cited Applications: WB
Cross Reactivity: Western blot EGFR from human cells
EGFR from other species may also be detectable
Host : Rabbit
Immunogen: Synthetic peptide corresponding to amino acids 1195-
1199 of human EGFR (protein accession number P00533)
Formulation: PBS pH 7.4, 0.02% sodium azide, 50% glycerol
Purification: Affinity chromatography
Stability: Store at 4
oC (add 0.1% NaN
3) for several months, and at -20
oC for longer periods.
For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For optimal performance, avoid repeated handling and multiple freeze/thaw cycles.
Scientific Background: EEGFR is the receptor for members of the EGF family and is a transmembrane glycoprotein that has tyrosine kinase activity. Binding of epidermal growth factor to EGFR induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation, differentiation, motility, and cell survival (1). Activation of EGFR triggers mitogenic signaling in gastrointestinal mucosa, and its expression is upregulated in colon cancers and most neoplasms (2). Activation of EGFR triggers activation of the ERK-signaling pathway in normal gastric epithelial and colon cancer cell lines. Inactivation of EGFR with selective inhibitors significantly reduces ERK2 activation, c-fos mRNA expression and cell proliferation.
References:
1. Wang K, et al: Epidermal growth factor receptor-deficient mice
have delayed primary endochondral ossification because of
defective osteoclast recruitment. J. Biol. Chem. 279: 53848-53856,
2004.
2. Kobayashi S, et al: EGFR mutation and resistance of non-small-cell
lung cancer to gefitinib. New Eng. J. Med. 352: 786-792, 2005.
 |
|
Sample Data: Representative western blot with Anti-EGFR (1:1000) using 3 μg,
10 μg and 30 μg of HeLa cell lysate. |
The Anti-EGFR product can be utilized in the following research areas, but not limited to:
AKT/PKB Pathway, Angiogenesis, Apoptosis/Autophagy, Cancer, Cardiovascular Disease, Cell Cycle, ERK/MAPK Pathway, Inflammation, Invasion/Metastasis, Metabolic Disorder, PKA/PKC Pathway, Receptor Tyrosine Kinases